| CPC A61N 1/37247 (2013.01) [A61N 1/0534 (2013.01); A61N 1/0551 (2013.01); A61N 1/36067 (2013.01); A61N 1/36167 (2013.01); A61N 1/0476 (2013.01); A61N 1/0509 (2013.01); A61N 1/0512 (2013.01); A61N 1/0514 (2013.01); A61N 1/0524 (2013.01); A61N 1/0531 (2013.01); A61N 1/0553 (2013.01); A61N 1/36062 (2017.08); A61N 1/36125 (2013.01); A61N 1/36132 (2013.01); A61N 1/36135 (2013.01); A61N 1/36171 (2013.01); A61N 1/36175 (2013.01); A61N 1/36178 (2013.01); A61N 1/36185 (2013.01); A61N 1/362 (2013.01); G16H 20/40 (2018.01)] | 17 Claims |

|
1. A neurostimulation (NS) system, comprising:
an implantable pulse generator (IPG) coupled to a lead having an array of electrodes, the IPG configured to deliver an NS therapy to a portion of the electrodes proximate to neural tissue of interest that is associated with a target region of a patient, wherein the NS therapy is defined by stimulation parameters;
an external device configured to communicate with the IPG;
memory configured to store program instructions;
one or more processors that, when executing the program instructions, are configured to:
obtain a first pharmacokinetic-stimulation (PS) profile for a drug, the first PS profile including values for one or more of the stimulation parameters that inversely vary with respect to time relative to efficacy of the drug following administration of the drug; and
receive an adjustment to the first PS profile to form a second PS profile, the adjustment adjusting one or more of the stimulation parameters to be utilized by the IPG.
|